Subscription plans
One avoided Phase-3 amendment (~$535K median) or one accelerated systematic review (~$141K manual) pays for a team plan many times over. Free for evaluation, Individual for solo experts, or a custom plan tailored to biotech and enterprise teams.
Evaluate against the ASCO 2025 dataset.
Academics, KOLs, prospects evaluating the platform, demo users
Personal license for solo experts.
Solo CI consultants, independent analysts, academics, KOLs, individual pharma professionals (personal use only)
For biotech and enterprise teams.
Biotech, mid-size biopharma, and large pharma — corporate licenses sized to your team, with training, support, and custom reporting.
All prices in USD. Annual billing. List prices will increase as proof points and customer logos accumulate.
Questions
Don’t see your question? Email the team and we’ll answer the same day.
Free (Demo) runs against the historical ASCO 2025 dataset and is view-only — no export. Individual unlocks the live ASCO 2026 library (abstracts, posters, orals, late-breakers) plus PDF export, but is strictly a personal license — corporate team use is prohibited.
Individual is one seat, strictly personal use. Custom team plans are corporate licenses with named seats — sized to your team during a brief sales conversation.
Median direct cost of a substantial Phase 3 protocol amendment is ~$535K (Tufts CSDD), and ~45% of amendments are considered avoidable. Even partial avoidance covers the largest tier many times over.
Enterprise life-sciences platforms typically quote $30K to six figures per year per seat. NousCongress is positioned in the underserved gap between those enterprise platforms and prosumer AI tools — decision-grade specialization at a fraction of incumbent pricing.
Let's turn your next congress into your next edge
30-minute live demo. Walk through the platform with your assets and your competitors — and leave with a sample summary report.
